Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 5/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242252 | 0.83 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3NOS2CCR5 | |
| SCHEMBL4586590 | 0.81 | CCR5 (0.47) | SLC6A2SLC6A4SLC6A3CCR5KCNH2 | |
| SCHEMBL4240573 | 0.81 | CCR5 (0.56) | SLC6A2SLC6A4SLC6A3CCR5KCNH2 | |
| SCHEMBL4240060 | 0.80 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3NOS2CCR5 | |
| SCHEMBL4244475 | 0.80 | CCR5 (0.54) | SLC6A2SLC6A4SLC6A3CCR5KCNH2 | |
| SCHEMBL4245108 | 0.79 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3NOS2CCR5 | |
| SCHEMBL4241353 | 0.77 | CCR5 (0.68) | CCR5 | |
| SCHEMBL4682986 | 0.74 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3NOS2CCR5 | |
| SCHEMBL13931449 | 0.73 | CCR5 (0.67) | CCR5 | |
| SCHEMBL312403 | 0.73 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3NOS2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | SLC6A2 3198/4885SLC6A4 3084/4885SLC6A3 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.